Patient characteristics of key treatment groups
| . | Total cohort . | Chemotherapy . | α-interferon . | HDACi . | Bexarotene . | Alemtuzumab . | Denileukin diftitox . | Autologous SCT . | Allogeneic SCT . | ECP . | TSEB . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | 198 . | 144 . | 68 . | 74 . | 20 . | 16 . | 22 . | 19 . | 9 . | 53 . | 65 . |
| Gender | |||||||||||
| Male | 112 (56.6) | 71 (49.3) | 34 (50.0) | 40 (54.1) | 15 (75.0) | 7 (43.7) | 13 (59.1) | 10 (52.6) | 5 (55.6) | 29 (54.7) | 34 (52.3) |
| Female | 86 (43.4) | 73 (50.7) | 34 (50.0) | 34 (45.9) | 5 (25.0) | 9 (56.3) | 9 (40.9) | 9 (47.4) | 4 (44.4) | 24 (45.3) | 31 (47.7) |
| Diagnosis | |||||||||||
| MF | 134 (67.7) | 105 (72.9) | 47 (69.1) | 53 (71.6) | 13 (65.0) | 5 (31.2) | 16 (72.7) | 14 (73.7) | 5 (55.6) | 10 (18.9) | 48 (73.8) |
| SS | 64 (32.3) | 39 (27.1) | 21 (30.9) | 21 (28.4) | 7 (35.0) | 11 (68.8) | 6 (27.3) | 5 (26.3) | 4 (44.4) | 43 (81.1) | 17 (26.2) |
| Stage at diagnosis | |||||||||||
| Early | 93 (43.0) | 66 (45.8) | 32 (47.1) | 35 (47.3) | 11 (55.0) | 2 (12.5) | 13 (59.1) | 5 (26.3) | 2 (22.2) | 3 (5.7) | 37 (56.9) |
| Advanced | 105 (57.0) | 78 (54.2) | 36 (52.9) | 39 (52.7) | 9 (45.0) | 14 (87.5) | 9 (40.9) | 14 (73.7) | 7 (77.8) | 50 (94.3) | 28 (43.1) |
| 1A | 51 (25.8) | 31 (21.5) | 12 (17.6) | 15 (20.3) | 5 (25.0) | 0 (0) | 8 (36.4) | 2 (10.5) | 0 (0) | 1 (1.9) | 14 (21.5) |
| 1B | 41 (20.7) | 35 (24.3) | 20 (29.4) | 19 (25.7) | 6 (30.0) | 2 (12.5) | 5 (22.7) | 3 (15.8) | 2 (22.2) | 2 (3.8) | 23 (35.4) |
| 2A | 1 (0.5) | 0 (0) | 0 (0) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 2B | 30 (15.2) | 35 (24.3) | 12 (17.7) | 13 (17.6) | 0 (0) | 3 (18.8) | 4 (18.2) | 5 (26.3) | 2 (22.2) | 0 (0) | 11 (16.9) |
| 3A | 6 (3.0) | 2 (1.4) | 3 (4.4) | 3 (4.0) | 1 (5.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (5.7) | 3 (4.6) |
| 3B | 8 (4.0) | 0 (0) | 3 (4.4) | 1 (1.4) | 1 (5.0) | 1 (6.2) | 0 (0) | 1 (5.3) | 2 (22.2) | 6 (11.3) | 0 (0) |
| 4A | 58 (29.3) | 38 (26.4) | 18 (26.5) | 21 (28.4) | 6 (30.0) | 10 (62.5) | 5 (22.7) | 6 (31.6) | 3 (33.3) | 41 (77.3) | 13 (20.0) |
| 4B | 3 (1.5) | 3 (2.1) | 0 (0) | 1 (1.4) | 1 (5.0) | 0 (0) | 0 (0) | 2 (10.5) | 0 (0) | 0 (0) | 1 (1.5) |
| Folliculotropic | |||||||||||
| Non-FT | 185 (93.5) | 141 (97.9) | 60 (88.2) | 66 (89.2) | 19 (95.0) | 16 (100) | 21 (95.5) | 17 (89.5) | 8 (88.9) | 53 (100) | 61 (93.8) |
| FT | 13 (6.5) | 3 (2.1) | 8 (11.8) | 8 (10.8) | 1 (5.0) | 0(0) | 1 (4.5) | 2 (10.5) | 1 (11.1) | 0 (0) | 4 (6.2) |
| Tumor (skin) score at treatment commencement | |||||||||||
| T1 | 33 (4.7) | 3 (2.2) | 5 (7.3) | 2 (2.7) | 1 (5.0) | 0 (0) | 1 (4.5) | 1 (5.6) | 1 (12.5) | 0 (0) | 2 (3.1) |
| T2 | 244 (35.0) | 40 (28.8) | 31 (45.6) | 24 (32.4) | 9 (45.0) | 2 (12.5) | 8 (36.4) | 4 (22.2) | 2 (25.0) | 6 (11.3) | 27 (42.2) |
| T3 | 168 (24.1) | 53 (38.1) | 11 (16.2) | 21 (28.4) | 2 (10.0) | 2 (12.5) | 5 (22.7) | 8 (44.4) | 3 (37.5) | 0 (0) | 20 (31.3) |
| T4 | 252 (36.2) | 43 (30.9) | 21 (30.9) | 27 (36.5) | 8 (40.0) | 12 (75.0) | 8 (36.4) | 5 (27.8) | 2 (25.0) | 47 (88.7) | 15 (23.4) |
| Nodal involvement at treatment commencement | |||||||||||
| N0 | 487 (69.9) | 82 (60.3) | 51 (77.3) | 52 (70.3) | 14 (70.0) | 9 (56.2) | 16 (76.2) | 7 (41.2) | 7 (87.5) | 35 (66.0) | 53 (82.8) |
| N1, N2, N3, Nx | 210 (30.1) | 54 (39.7) | 15 (22.7) | 22 (29.7) | 6 (30.0) | 7 (43.8) | 5 (23.8) | 10 (58.8) | 1 (12.5) | 18 (34.0) | 11 (17.2) |
| Visceral involvement at treatment commencement | |||||||||||
| M0 | 680 (97.4) | 133 (95.7) | 68 (100) | 73 (98.7) | 19 (95.0) | 16 (100) | 21 (95.5) | 14 (77.8) | 8 (100) | 52 (98.1) | 63 (96.9) |
| M1 | 18 (2.6) | 6 (4.3) | 0 (0) | 1 (1.3) | 1 (5.0) | 0 (0) | 1 (4.5) | 4 (22.2) | 0 (0) | 1 (1.9) | 2 (3.1) |
| Blood involvement at treatment commencement | |||||||||||
| B0 | 484 (69.4) | 102 (73.4) | 49 (72.1) | 54 (73.0) | 16 (80.0) | 7 (43.8) | 18 (81.8) | 11 (61.1) | 5 (62.5) | 10 (18.9) | 52 (80.0) |
| B1 | 38 (5.5) | 1 (0.7) | 3 (4.4) | 5 (6.7) | 0 (0) | 0 (0) | 1 (4.6) | 2 (11.1) | 1 (12.5) | 8 (15.1) | 4 (6.1) |
| B2 | 175 (25.1) | 36 (25.9) | 16 (23.5) | 15 (20.3) | 4 (20.0) | 9 (56.2) | 3 (13.6) | 5 (27.8) | 2 (25.0) | 35 (66.0) | 9 (13.9) |
| LCT at treatment commencement | |||||||||||
| Non-LCT | 615 (86.7) | 106 (73.6) | 64 (94.1) | 60 (81.1) | 18 (90.0) | 16 (100) | 20 (90.9) | 11 (57.9) | 8 (88.9) | 53 (100) | 62 (95.4) |
| LCT | 94 (13.3) | 38 (26.4) | 4 (5.9) | 14 (18.9) | 2 (10.0) | 0 (0) | 2 (9.1) | 8 (42.1) | 1 (11.1) | 0 (0) | 3 (4.6) |
| Median age at diagnosis, y | 61.8 | 56.8 | 57.8 | 58.0 | 64.6 | 57.7 | 60.7 | 58.9 | 40.6 | 64.7 | 67.4 |
| Median age at treatment, y | 62.5 | 62.6 | 60.3 | 63.4 | 66.6 | 61.5 | 62.9 | 59.9 | 42.1 | 65.8 | 67.7 |
| Median treatment line (range) | 3 (1-13) | 4 (1-12) | 2 (1-9) | 3 (1-9) | 2 (1-11) | 3.5 (1-8) | 4 (1-11) | 3 (1-11) | 6 (2-10) | 2 (1-11) | 2 (1-8) |
| . | Total cohort . | Chemotherapy . | α-interferon . | HDACi . | Bexarotene . | Alemtuzumab . | Denileukin diftitox . | Autologous SCT . | Allogeneic SCT . | ECP . | TSEB . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | 198 . | 144 . | 68 . | 74 . | 20 . | 16 . | 22 . | 19 . | 9 . | 53 . | 65 . |
| Gender | |||||||||||
| Male | 112 (56.6) | 71 (49.3) | 34 (50.0) | 40 (54.1) | 15 (75.0) | 7 (43.7) | 13 (59.1) | 10 (52.6) | 5 (55.6) | 29 (54.7) | 34 (52.3) |
| Female | 86 (43.4) | 73 (50.7) | 34 (50.0) | 34 (45.9) | 5 (25.0) | 9 (56.3) | 9 (40.9) | 9 (47.4) | 4 (44.4) | 24 (45.3) | 31 (47.7) |
| Diagnosis | |||||||||||
| MF | 134 (67.7) | 105 (72.9) | 47 (69.1) | 53 (71.6) | 13 (65.0) | 5 (31.2) | 16 (72.7) | 14 (73.7) | 5 (55.6) | 10 (18.9) | 48 (73.8) |
| SS | 64 (32.3) | 39 (27.1) | 21 (30.9) | 21 (28.4) | 7 (35.0) | 11 (68.8) | 6 (27.3) | 5 (26.3) | 4 (44.4) | 43 (81.1) | 17 (26.2) |
| Stage at diagnosis | |||||||||||
| Early | 93 (43.0) | 66 (45.8) | 32 (47.1) | 35 (47.3) | 11 (55.0) | 2 (12.5) | 13 (59.1) | 5 (26.3) | 2 (22.2) | 3 (5.7) | 37 (56.9) |
| Advanced | 105 (57.0) | 78 (54.2) | 36 (52.9) | 39 (52.7) | 9 (45.0) | 14 (87.5) | 9 (40.9) | 14 (73.7) | 7 (77.8) | 50 (94.3) | 28 (43.1) |
| 1A | 51 (25.8) | 31 (21.5) | 12 (17.6) | 15 (20.3) | 5 (25.0) | 0 (0) | 8 (36.4) | 2 (10.5) | 0 (0) | 1 (1.9) | 14 (21.5) |
| 1B | 41 (20.7) | 35 (24.3) | 20 (29.4) | 19 (25.7) | 6 (30.0) | 2 (12.5) | 5 (22.7) | 3 (15.8) | 2 (22.2) | 2 (3.8) | 23 (35.4) |
| 2A | 1 (0.5) | 0 (0) | 0 (0) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 2B | 30 (15.2) | 35 (24.3) | 12 (17.7) | 13 (17.6) | 0 (0) | 3 (18.8) | 4 (18.2) | 5 (26.3) | 2 (22.2) | 0 (0) | 11 (16.9) |
| 3A | 6 (3.0) | 2 (1.4) | 3 (4.4) | 3 (4.0) | 1 (5.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (5.7) | 3 (4.6) |
| 3B | 8 (4.0) | 0 (0) | 3 (4.4) | 1 (1.4) | 1 (5.0) | 1 (6.2) | 0 (0) | 1 (5.3) | 2 (22.2) | 6 (11.3) | 0 (0) |
| 4A | 58 (29.3) | 38 (26.4) | 18 (26.5) | 21 (28.4) | 6 (30.0) | 10 (62.5) | 5 (22.7) | 6 (31.6) | 3 (33.3) | 41 (77.3) | 13 (20.0) |
| 4B | 3 (1.5) | 3 (2.1) | 0 (0) | 1 (1.4) | 1 (5.0) | 0 (0) | 0 (0) | 2 (10.5) | 0 (0) | 0 (0) | 1 (1.5) |
| Folliculotropic | |||||||||||
| Non-FT | 185 (93.5) | 141 (97.9) | 60 (88.2) | 66 (89.2) | 19 (95.0) | 16 (100) | 21 (95.5) | 17 (89.5) | 8 (88.9) | 53 (100) | 61 (93.8) |
| FT | 13 (6.5) | 3 (2.1) | 8 (11.8) | 8 (10.8) | 1 (5.0) | 0(0) | 1 (4.5) | 2 (10.5) | 1 (11.1) | 0 (0) | 4 (6.2) |
| Tumor (skin) score at treatment commencement | |||||||||||
| T1 | 33 (4.7) | 3 (2.2) | 5 (7.3) | 2 (2.7) | 1 (5.0) | 0 (0) | 1 (4.5) | 1 (5.6) | 1 (12.5) | 0 (0) | 2 (3.1) |
| T2 | 244 (35.0) | 40 (28.8) | 31 (45.6) | 24 (32.4) | 9 (45.0) | 2 (12.5) | 8 (36.4) | 4 (22.2) | 2 (25.0) | 6 (11.3) | 27 (42.2) |
| T3 | 168 (24.1) | 53 (38.1) | 11 (16.2) | 21 (28.4) | 2 (10.0) | 2 (12.5) | 5 (22.7) | 8 (44.4) | 3 (37.5) | 0 (0) | 20 (31.3) |
| T4 | 252 (36.2) | 43 (30.9) | 21 (30.9) | 27 (36.5) | 8 (40.0) | 12 (75.0) | 8 (36.4) | 5 (27.8) | 2 (25.0) | 47 (88.7) | 15 (23.4) |
| Nodal involvement at treatment commencement | |||||||||||
| N0 | 487 (69.9) | 82 (60.3) | 51 (77.3) | 52 (70.3) | 14 (70.0) | 9 (56.2) | 16 (76.2) | 7 (41.2) | 7 (87.5) | 35 (66.0) | 53 (82.8) |
| N1, N2, N3, Nx | 210 (30.1) | 54 (39.7) | 15 (22.7) | 22 (29.7) | 6 (30.0) | 7 (43.8) | 5 (23.8) | 10 (58.8) | 1 (12.5) | 18 (34.0) | 11 (17.2) |
| Visceral involvement at treatment commencement | |||||||||||
| M0 | 680 (97.4) | 133 (95.7) | 68 (100) | 73 (98.7) | 19 (95.0) | 16 (100) | 21 (95.5) | 14 (77.8) | 8 (100) | 52 (98.1) | 63 (96.9) |
| M1 | 18 (2.6) | 6 (4.3) | 0 (0) | 1 (1.3) | 1 (5.0) | 0 (0) | 1 (4.5) | 4 (22.2) | 0 (0) | 1 (1.9) | 2 (3.1) |
| Blood involvement at treatment commencement | |||||||||||
| B0 | 484 (69.4) | 102 (73.4) | 49 (72.1) | 54 (73.0) | 16 (80.0) | 7 (43.8) | 18 (81.8) | 11 (61.1) | 5 (62.5) | 10 (18.9) | 52 (80.0) |
| B1 | 38 (5.5) | 1 (0.7) | 3 (4.4) | 5 (6.7) | 0 (0) | 0 (0) | 1 (4.6) | 2 (11.1) | 1 (12.5) | 8 (15.1) | 4 (6.1) |
| B2 | 175 (25.1) | 36 (25.9) | 16 (23.5) | 15 (20.3) | 4 (20.0) | 9 (56.2) | 3 (13.6) | 5 (27.8) | 2 (25.0) | 35 (66.0) | 9 (13.9) |
| LCT at treatment commencement | |||||||||||
| Non-LCT | 615 (86.7) | 106 (73.6) | 64 (94.1) | 60 (81.1) | 18 (90.0) | 16 (100) | 20 (90.9) | 11 (57.9) | 8 (88.9) | 53 (100) | 62 (95.4) |
| LCT | 94 (13.3) | 38 (26.4) | 4 (5.9) | 14 (18.9) | 2 (10.0) | 0 (0) | 2 (9.1) | 8 (42.1) | 1 (11.1) | 0 (0) | 3 (4.6) |
| Median age at diagnosis, y | 61.8 | 56.8 | 57.8 | 58.0 | 64.6 | 57.7 | 60.7 | 58.9 | 40.6 | 64.7 | 67.4 |
| Median age at treatment, y | 62.5 | 62.6 | 60.3 | 63.4 | 66.6 | 61.5 | 62.9 | 59.9 | 42.1 | 65.8 | 67.7 |
| Median treatment line (range) | 3 (1-13) | 4 (1-12) | 2 (1-9) | 3 (1-9) | 2 (1-11) | 3.5 (1-8) | 4 (1-11) | 3 (1-11) | 6 (2-10) | 2 (1-11) | 2 (1-8) |
Early stage includes IA-IIA. Advanced stage includes IIB-IVB. TNMB scores are as defined by the WHO-EORTC revised staging criteria. All values are presented as n (%) unless otherwise noted.
FT, folliculotropic; LCT, large-cell transformation; SCT, stem cell transplant; TSEB, total skin electron beam.